Literature DB >> 33742106

Cancer genome datamining and functional genetic analysis implicate mechanisms of ATM/ATR dysfunction underpinning carcinogenesis.

Erik Waskiewicz1, Michalis Vasiliou1, Isaac Corcoles-Saez1, Rita S Cha2.   

Abstract

ATM and ATR are conserved regulators of the DNA damage response linked to cancer. Comprehensive DNA sequencing efforts identified ~4,000 cancer-associated mutations in ATM/ATR; however, their cancer implications remain largely unknown. To gain insights, we identify functionally important conserved residues in ATM, ATR and budding yeast Mec1ATR via cancer genome datamining and a functional genetic analysis, respectively. Surprisingly, only a small fraction of the critical residues is in the active site of the respective enzyme complexes, implying that loss of the intrinsic kinase activity is infrequent in carcinogenesis. A number of residues are solvent accessible, suggestive of their involvement in interacting with a protein-partner(s). The majority, buried inside the respective enzyme complexes, might play a structural or regulatory role. Together, these findings identify evolutionarily conserved ATM, ATR, and Mec1ATR residues involved in diverse aspects of the enzyme function and provide fresh insights into the elusive genotype-phenotype relationships in ATM/ATR and their cancer-associated variants.

Entities:  

Year:  2021        PMID: 33742106      PMCID: PMC7979806          DOI: 10.1038/s42003-021-01884-x

Source DB:  PubMed          Journal:  Commun Biol        ISSN: 2399-3642


  46 in total

Review 1.  Cell cycle checkpoint signaling through the ATM and ATR kinases.

Authors:  R T Abraham
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

2.  ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1.

Authors:  Zhongsheng You; Charly Chahwan; Julie Bailis; Tony Hunter; Paul Russell
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 3.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

Review 4.  ATM Mutations in Cancer: Therapeutic Implications.

Authors:  Michael Choi; Thomas Kipps; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2016-07-13       Impact factor: 6.261

5.  Bioinformatic analyses implicate the collaborating meiotic crossover/chiasma proteins Zip2, Zip3, and Spo22/Zip4 in ubiquitin labeling.

Authors:  Jason Perry; Nancy Kleckner; G Valentin Börner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-28       Impact factor: 11.205

6.  Characterization of the activation domain of the Rad53 checkpoint kinase.

Authors:  Simona Fiorani; Guendalina Mimun; Laura Caleca; Daniele Piccini; Achille Pellicioli
Journal:  Cell Cycle       Date:  2008-02-15       Impact factor: 4.534

7.  TopBP1 activates ATR through ATRIP and a PIKK regulatory domain.

Authors:  Daniel A Mordes; Gloria G Glick; Runxiang Zhao; David Cortez
Journal:  Genes Dev       Date:  2008-06-01       Impact factor: 11.361

Review 8.  Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Authors:  Alice Bradbury; Sally Hall; Nicola Curtin; Yvette Drew
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

9.  Budding yeast ATM/ATR control meiotic double-strand break (DSB) levels by down-regulating Rec114, an essential component of the DSB-machinery.

Authors:  Jesús A Carballo; Silvia Panizza; Maria Elisabetta Serrentino; Anthony L Johnson; Marco Geymonat; Valérie Borde; Franz Klein; Rita S Cha
Journal:  PLoS Genet       Date:  2013-06-27       Impact factor: 5.917

10.  Structural insights into the activation of ATM kinase.

Authors:  Jianxiong Xiao; Mengjie Liu; Yilun Qi; Yuriy Chaban; Chao Gao; Beiqing Pan; Yuan Tian; Zishuo Yu; Jie Li; Peijun Zhang; Yanhui Xu
Journal:  Cell Res       Date:  2019-07-18       Impact factor: 46.297

View more
  1 in total

1.  Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer.

Authors:  Georgios I Papageorgiou; Evangelos Fergadis; Nikos Skouteris; Evridiki Christakos; Sergios A Tsakatikas; Evangelos Lianos; Christos Kosmas
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.